

December 8, 2015
Symbio Pharmaceuticals Limited
Fuminori Yoshida
Representative Director
President & Chief Executive Officer

Onconova Therapeutics Announces Enrollment of First Patient in Global Phase 3 Trial for IV Rigosertib

TOKYO, Japan, December 8, 2015 --- Symbio Pharmaceuticals Limited (Headquarters: Tokyo, “Symbio”) announced today that its U.S. partner, Onconova Therapeutics, Inc. (Headquarters: Newtown, PA, “Onconova”) has enrolled the first patient in the global Phase 3 trial (“04-30” or “INSPIRE” trial) for IV rigosertib as a treatment for higher-risk myelodysplastic syndromes after failure of hypomethylating agent therapy.

For more details on this press release, please visit Onconova’s homepage at <http://investor.onconova.com/releases.cfm>

Symbio has made the decision to participate in the global Phase 3 trial (please refer to Symbio’s press release dated October 19, 2015) and plans to have Japanese patients enrolled in this global Phase 3 trial. Marketing approvals in Japan, the U.S. and EU are expected to be received concurrently.

[Contact]

Investor Relations

Tel: +81 (0)3 5472 1125

About Onconova Therapeutics, Inc.

Onconova Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel products to treat cancer. Onconova's clinical and pre-clinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells, while causing minimal damage to normal cells. In addition to rigosertib, Onconova's most advanced drug candidate under development, two other drug candidates are in clinical trials and several other compounds in the pre-clinical stage of development. For more information, please visit <http://www.onconova.com>.

About Symbio Pharmaceuticals Limited

Symbio Pharmaceuticals Limited was established in March, 2005, by Fuminori Yoshida who previously served concurrently as Corporate VP of Amgen Inc. and founding President of Amgen

Japan. The company's underlying corporate mission is to "deliver hope to patients in need" as it aspires to be a leading specialty pharmaceutical company in Asia Pacific dedicated to addressing underserved medical needs with main therapeutic focus in oncology, hematology and pain management.